EMEA-001773-PIP01-15

Key facts

Active substance
DNA, d(P-thio)([2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]rG-G-T-T-A-m5C-A-T-G-A-A-[2'-0-(2-methoxyethyl)]rA-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethy l)]m5rC-[2'-0-(2-methoxyethyl)]m5rC), sodium salt
Therapeutic area
Neurology
Decision number
P/0181/2015
PIP number
EMEA-001773-PIP01-15
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of transthyretin-related amyloidosis (ATTR amyloidosis)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Isis Pharmaceuticals, Inc.

Email: info@akceatx.com
Tel. + 353 (0) 1 477 3197

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating